Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs)

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Frank Behrens
  • Paul P Tak
  • Mikkel Østergaard
  • Rumen Stoilov
  • Piotr Wiland
  • Thomas W Huizinga
  • Vadym Y Berenfus
  • Stoyanka Vladeva
  • Juergen Rech
  • Andrea Rubbert-Roth
  • Mariusz Korkosz
  • Dmitriy Rekalov
  • Igor A Zupanets
  • Bo J Ejbjerg
  • Jens Geiseler
  • Julia Fresenius
  • Roman P Korolkiewicz
  • Arndt J Schottelius
  • Harald Burkhardt
Vis graf over relationer

OBJECTIVES: To determine the safety, tolerability and signs of efficacy of MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF), in patients with rheumatoid arthritis (RA).

METHODS: Patients with active, moderate RA were enrolled in a randomised, multicentre, double-blind, placebo-controlled, dose-escalation trial of intravenous MOR103 (0.3, 1.0 or 1.5 mg/kg) once a week for 4 weeks, with follow-up to 16 weeks. The primary outcome was safety.

RESULTS: Of the 96 randomised and treated subjects, 85 completed the trial (n=27, 24, 22 and 23 for pooled placebo and MOR103 0.3, 1.0 and 1.5 mg/kg, respectively). Treatment emergent adverse events (AEs) in the MOR103 groups were mild or moderate in intensity and generally reported at frequencies similar to those in the placebo group. The most common AE was nasopharyngitis. In two cases, AEs were classified as serious because of hospitalisation: paronychia in a placebo subject and pleurisy in a MOR103 0.3 mg/kg subject. Both patients recovered fully. In exploratory efficacy analyses, subjects in the MOR103 1.0 and 1.5 mg/kg groups showed significant improvements in Disease Activity Score-28 scores and joint counts and significantly higher European League Against Rheumatism response rates than subjects receiving placebo. MOR103 1.0 mg/kg was associated with the largest reductions in disease activity parameters.

CONCLUSIONS: MOR103 was well tolerated and showed preliminary evidence of efficacy in patients with active RA. The data support further investigation of this monoclonal antibody to GM-CSF in RA patients and potentially in those with other immune-mediated inflammatory diseases.

TRIAL REGISTRATION NUMBER: NCT01023256.

OriginalsprogEngelsk
TidsskriftAnnals of the Rheumatic Diseases
Vol/bind74
Udgave nummer6
Sider (fra-til)1058-64
Antal sider7
ISSN0003-4967
DOI
StatusUdgivet - jun. 2015

ID: 46257417